Document:

Exhibit 10.17

 

Forbearance
Agreement

 

This Forbearance
Agreement (this “Agreement”) is entered into as of September 3, 2021 by and among JR-HD Enterprises III, LLC, a Delaware
limited liability company (“JRD”) and Electromedical Technologies, Inc., a Delaware corporation (“EMED”).
Capitalized terms used in this Agreement without definition shall have the meanings given to them in the Note (defined below).

 

WHEREAS,
EMED sold and issued to JRD certain Secured Convertible Promissory Notes (“Notes”), as follows:

 

(i) July 21,
2020 in the principal amount of $107,500, 8% interest with a maturity date of July 21, 2021;

 

(ii) August 4,
2020 in the principal amount of $215,000, 10% interest, with a maturity date of August 4, 2021.

 

(iii) September 3,
2020 in the principal amount of $107,500, 8% interest, with a maturity date of September 3, 2021;

 

(iv) November 3,
2020 in the principal amount of $244,852.94, 8% interest, with a maturity date of November 3, 2021;

 

(v) December 3,
2020 in the principal amount of $110,000, 8% interest, with a maturity date of December 3, 2021;

 

and together with
the Notes and all other documents entered into in conjunction therewith, the “Transaction Documents.”

 

WHEREAS, EMED defaulted
on the July 21, 2020 Note and the August 4, 2020 Note by failing to pay principal and interest upon the respective maturity
dates.

 

WHEREAS,
as a result of the defaults, JRD has the right to, among other things, declare all or any portion of the then outstanding principal amount
of the Notes, together with all accrued and unpaid interest thereon, due, and payable, and the Notes shall thereupon become, immediately
due and payable in cash and (ii) JRD shall have the right to pursue any other remedies that it may have under applicable Law.

 

WHEREAS,
No new or additional consideration is being provided in connection with this Agreement other than the modification of terms as provided
herein.

 

WHEREAS,
JRD has agreed, subject to the terms, conditions and understandings expressed in this Agreement, to: (i) refrain and forbear temporarily
from exercising and enforcing remedies against EMED for the Defaults as provided in this Agreement; and, (ii) amending the Notes
to extend their respective maturity dates consistent with the terms and conditions of this Agreement.

 

    Page 1 of 8

     

    

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1. Recitals
and Definitions. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Agreement are true
and accurate, are contractual in nature, and are hereby incorporated into and made a part of this Agreement.

 

2. Forbearance.
The Notes are hereby amended pursuant to Sections 5(f) of the respective Notes, to change the maturity dates of each Note to a respective
date six (6) months from each Note’s original maturity date (the "Forbearance"). For the avoidance of doubt,
the amended maturity date schedule is:

 

July 21, 2020
Note matures on January 21, 2022;

 

August 4,
2020 Note matures on February 4, 2022;

 

September 3,
2020 Note matures on March 3, 2022;

 

November 3,
2020 Note matures on May 3, 2022; and,

 

December 3,
2020 Note matures on June 3, 2022.

 

The Notes are further
amended to delete the prepayment cost provision in Section 2(b) of the Notes, allowing EMED to make a prepayment of principal
and interest due under the Notes without being subject to a 20% prepayment cost being added to the amount of the Principal Amount and
accrued and unpaid interest so prepaid at such time.

 

3. EMED Payment.
As consideration for JRD’s Forbearance, EMED agrees to make cash payments to JRD of twelve thousand, five hundred dollars ($12,500.00)
each on the following schedule:

 

(i) Upon
the execution of this Agreement;

 

(ii) September 30,
2021;

 

(iii) October 31,
2021;

 

(iv) November 30,
2021; and,

 

(v) December 31,
2021; and,

 

(vi) January 15,
2021

 

EMED’s payments
shall be credited first against interest due on the Notes in Default, and then to the payment of Principal on the July 21, 2020
Note. In consideration of EMED’s timely payments, JRD agrees to the Forbearance schedule in Section 2, during which time JRD
will not take any action to collect on the Notes.

 

In the event that
EMED does not make any of the scheduled payments, any unpaid amounts shall be added to the dollar value of shares issuable under 3(a) below.

 

    Page 2 of 8

     

    

 

a.
As additional consideration for JRD’s Forbearance and the amendment to the Notes, on January 15, 2022, EMED agrees to issue
to JRD that number of shares of EMED common stock equal to one hundred thousand dollars ($100,000), discounted by 25%, based on the previous
15-day average closing price of EMED’s common stock reported on OTC Markets. The common stock will be unregistered and restricted
and will carry with it the customary Rule 144 restrictive legend. The common stock cannot be sold in the public markets unless EMED
either registers the common stock or determines that an exemption from registration exists. For purposes of Rule 144(d), JRD’s
payment of consideration for the stock issuance shall be the effective date hereof.

 

4. Ratification
of the Notes. The Notes, as amended by this Agreement, shall be and remain in full force and effect in accordance with their respective
terms, and are hereby ratified and confirmed in all respects. EMED acknowledges and agrees that the Outstanding Principal Balances of
the Notes as of the date hereof is $784,852.94. EMED acknowledges that it is unconditionally obligated to pay the Outstanding Balance
and all accrued interest and represents that such obligation is not subject to any defenses, rights of offset or counterclaims. No Forbearance
or waiver other than as expressly set forth herein may be implied by this Agreement. Except as expressly set forth herein, the execution,
delivery, and performance of this Agreement shall not operate as a waiver of, or as an amendment to, any right, power, or remedy of JRD
under the Notes or the Transaction Documents, as in effect prior to the date hereof.

 

5. Failure to
Comply. EMED understands that the Forbearance shall terminate immediately upon any Event of Default after the respective maturity
dates in Section 2 above, and that in such case, JRD may seek all recourse available to it under the terms of the Notes, this Agreement,
any other Transaction Document, or applicable law. For the avoidance of any doubt, the termination of the Forbearance pursuant to this
Section shall not terminate, limit, or modify any other provision of this Agreement.

 

    Page 3 of 8

     

    

 

6. Representations,
Warranties and Agreements. In order to induce JRD to enter into this Agreement, EMED, for itself, and for its affiliates,
successors and assigns, hereby acknowledges, represents, warrants, and agrees as follows: (a) EMED has full power and authority
to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which have been duly
authorized by all proper and necessary action. No consent, approval, filing or registration with or notice to any governmental
authority is required as a condition to the validity of this Agreement or the performance of any of the obligations of EMED
hereunder. (b) Any Event of Default which may have occurred under the Notes has not been, is not hereby, and shall not be
deemed to be waived by JRD, expressly, impliedly, through course of conduct or otherwise except upon full satisfaction of EMED's
obligations under this Agreement. The agreement of JRD to refrain and forbear from exercising any rights and remedies by reason of
any existing default or any future default shall not constitute a waiver of consent to, or condoning of, any other future default.
For the avoidance of any doubt, the Forbearance described herein only applies to the Defaults, and shall not constitute a waiver or
forbearance of any other rights or remedies available to JRD with respect to any other Events of Default under the Notes or other
breach of the Transaction Documents or this Agreement by EMED. (c) All understandings, representations, warranties, and
recitals contained or expressed in this Agreement are true, accurate, complete, and correct in all respects; and no such
understanding, representation, warranty, or recital fails or omits to state or otherwise disclose any material fact or information
necessary to prevent such understanding, representation, warranty, or recital from being misleading. EMED acknowledges and agrees
that JRD has been induced in part to enter into this Agreement based upon JRD's justifiable reliance on the truth, accuracy, and
completeness of all understandings, representations, warranties, and recitals contained in this Agreement. There is no fact known to
EMED or which should be known to EMED which EMED has not disclosed to JRD on or prior to the date hereof which would or could
materially and adversely affect the understandings of JRD expressed in this Agreement or any representation, warranty, or recital
contained in this Agreement. (d) Except as expressly set forth in this Agreement, EMED acknowledges and agrees that neither the
execution and delivery of this Agreement nor any of the terms, provisions, covenants, or agreements contained in this Agreement
shall in any manner release, impair, lessen, modify, waive, or otherwise affect the liability and obligations of EMED under the
terms of the Notes or any of the other Transaction Documents. (e) EMED has no defenses, affirmative or otherwise, rights of
setoff, rights of recoupment, claims, counterclaims, actions or causes of action of any kind or nature whatsoever against JRD,
directly or indirectly, arising out of, based upon, or in any manner connected with, the transactions contemplated hereby, whether
known or unknown, which occurred, existed, was taken, permitted, or begun prior to the execution of this Agreement and occurred,
existed, was taken, permitted or begun in accordance with, pursuant to, or by virtue of any of the terms or conditions of the
Transaction Documents. To the extent any such defenses, affirmative or otherwise, rights of setoff, rights of recoupment, claims,
counterclaims, actions or causes of action exist or existed, such defenses, rights, claims, counterclaims, actions and causes of
action are hereby waived, discharged, and released. EMED hereby acknowledges and agrees that the execution of this Agreement by JRD
shall not constitute an acknowledgment of or admission by JRD of the existence of any claims or of liability for any matter or
precedent upon which any claim or liability may be asserted. (f) EMED hereby acknowledges that it has freely and voluntarily
entered into this Agreement after an adequate opportunity and sufficient period of time to review, analyze, and discuss (i) all
terms and conditions of this Agreement, (ii) any and all other documents executed and delivered in connection with the
transactions contemplated by this Agreement, and (iii) all factual and legal matters relevant to this Agreement and/or any and
all such other documents, with counsel freely and independently selected by EMED (or had the opportunity to be represented by
counsel). The Parties further acknowledge and agree that each has actively and with full understanding participated in the
negotiation of this Agreement and all other documents executed and delivered in connection with this Agreement after consultation
and review with their respective counsel (or had the opportunity to be represented by counsel), that all of the terms and conditions
of this Agreement and the other documents executed and delivered in connection with this Agreement have been negotiated at arm's
length, and that this Agreement and all such other documents have been negotiated, prepared, and executed without fraud, duress,
undue influence, or coercion of any kind or nature whatsoever having been exerted by or imposed upon any party by any other party.
No provision of this Agreement or such other documents shall be construed against or interpreted to the disadvantage of any party by
any court or other governmental or judicial authority by reason of such party having or being deemed to have structured, dictated,
or drafted such provision. (g) There are no proceedings or investigations pending or threatened before any court or arbitrator
or before or by, any governmental, administrative, or judicial authority or agency, or arbitrator, against EMED. (h) There is
no statute, regulation, rule, order or judgment and no provision of any mortgage, indenture, contract, or other agreement binding on
EMED, which would prohibit or cause a default under or in any way prevent the execution, delivery, performance, compliance, or
observance of any of the terms and conditions of this Agreement and/or any of the other documents executed and delivered in
connection with this Agreement. (i) EMED is solvent as of the date of this Agreement, and none of the terms or provisions of
this Agreement shall have the effect of rendering EMED insolvent. The terms and provisions of this Agreement and all other
instruments and agreements entered into in connection herewith are being given for full and fair consideration and exchange of
value.

 

    Page 4 of 8

     

    

 

7. Most Favored
Nation Status. Effective after January 15, 2022, if EMED engages in any financing transactions with a third-party investor,
EMED will provide JRD with written notice thereof promptly, but in no event less than 10 days prior to closing any financing transactions.
Included with the Notice shall be a copy of all documentation relating to such financing transaction and shall include, upon written
request of JRD, any additional information related to such subsequent investment as may be reasonably requested by JRD. In the event
the subsequent investment is for consideration per share less than the fixed price of the Notes, i.e., $0.50 per share, EMED agrees to
amend and restate the Notes to reduce the conversion price of the Notes to an amount equal to the new issuance price of the subsequent
investment. Notwithstanding the foregoing, this Section 7 shall not apply in respect of (i) an Exempt Issuance, or (ii) an
underwritten public offering of Common Stock. “Exempt Issuance” means the issuance of: (a) shares of Common Stock or
options to employees, officers, consultants, advisors or directors of EMED pursuant to any stock or option plan duly adopted for such
purpose by a majority of the members of the Board of Directors or a majority of the members of a committee of directors established for
such purpose, and, (b) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the directors
of EMED, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company
in a business synergistic with the business of EMED and in which EMED receives benefits in addition to the investment of funds.

 

8. Headings.
The headings contained in this Agreement are for reference purposes only and do not affect in any way the meaning or interpretation of
this Agreement.

 

9. Arbitration.
By its execution of this Agreement, each party agrees to be bound by the Arbitration Provisions (as defined in Section 6.09 of the
Securities Purchase Agreements) set forth as an exhibit to each Securities Purchase [or Note Purchase] Agreements and the parties agree
to submit all Claims arising under this Agreement or any Transaction Document or other agreement between the parties and their affiliates
to binding arbitration pursuant to the Arbitration Provisions.

 

10. Governing
Law; Venue. This Agreement, and all matters based upon, arising out of or relating in any way to the Notes or the Transaction Documents,
including all disputes, claims or causes of action arising out of or relating to the this Agreement, the Notes or the Transaction Documents
as well as the interpretation, construction, performance and enforcement of this Agreement, the Notes and Transaction Documents, shall
be governed by the laws of the United States and the State of Delaware, without regard to any jurisdiction’s conflict-of-laws principles.
Subject to Section 6.09, of the Securities Purchase [or Note Purchase] Agreements, each party consents, pursuant to Section 6.07
of the respective Securities Purchase [or Note Purchase] Agreements, to the jurisdiction of the State and Federal Courts in the State
of New York, and each irrevocably submits to the jurisdiction of said courts and waive any objection to the convenience of such jurisdiction
or venue.

 

11. Counterparts.
This Agreement may be executed in any number of counterparts with the same effect as if all signing parties had signed the same document.
All counterparts shall be construed together and constitute the same instrument. The exchange of copies of this Agreement and of signature
pages by facsimile transmission or other electronic transmission (including email) shall constitute effective execution and delivery
of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted
by facsimile transmission or other electronic transmission (including email) shall be deemed to be their original signatures for all
purposes.

 

    Page 5 of 8

     

    

 

12. Attorneys'
Fees. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this Agreement, the parties
agree that the party who is awarded the most money shall be deemed the prevailing party for all purposes and shall therefore be entitled
to an additional award of the full amount of the attorneys' fees and expenses paid by such prevailing party in connection with the arbitration,
litigation and/or dispute without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and
expenses. Nothing herein shall restrict or impair an arbitrator's or a court's power to award fees and expenses for frivolous or bad
faith pleading.

 

13. No Reliance.
EMED acknowledges and agrees that neither JRD nor any of its officers, directors, members, managers, equity holders, representatives
or agents has made any representations or warranties to EMED or any of its agents, representatives, officers, directors, or employees
except as expressly set forth in this Agreement and the Transaction Documents and, in making its decision to enter into the transactions
contemplated by this Agreement, EMED is not relying on any representation, warranty, covenant or promise of JRD or its officers, directors,
members, managers, equity holders, agents or representatives other than as set forth in this Agreement.

 

14. Severability.
If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the objective of the
parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect.

 

15. Entire
Agreement. This Agreement, together with the Transaction Documents, and all other documents referred to herein, supersedes all
other prior oral or written agreements between EMED, JRD, its affiliates and persons acting on its behalf with respect to the
matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither JRD nor EMED
makes any representation, warranty, covenant or undertaking with respect to such matters.

 

16. Amendments.
This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision of this Agreement may
be waived except in writing signed by the party against whom such waiver is sought to be enforced.

 

17. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by JRD hereunder may be assigned
by JRD to a third party, including its financing sources, in whole or in part. EMED may not assign this Agreement or any of its obligations
herein without the prior written consent of JRD.

 

    Page 6 of 8

     

    

 

18. Continuing
Enforceability; Conflict Between Documents. Except as otherwise modified by this Agreement, each Note and each of the other Transaction
Documents shall remain in full force and effect, enforceable in accordance with all of its original terms and provisions. This Agreement
shall not be effective or binding unless and until it is fully executed and delivered by JRD and EMED. If there is any conflict between
the terms of this Agreement, on the one hand, and the Note or any other Transaction Document, on the other hand, the terms of this Agreement
shall prevail.

 

19. Time of
Essence. Time is of the essence with respect to each and every provision of this Agreement.

 

20. Notices.
Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under this Agreement to be
given to EMED or JRD shall be given as set forth in the "Notices" section of the Purchase Agreement.

 

21. Further
Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments, and documents, as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

22. Notices.
Notices. Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if personally
delivered to it or sent by email, overnight courier or registered mail or certified mail, postage prepaid, addressed as follows:

 

if to EMED, to:

 

Electromedical
Technologies, Inc. 

Attn: Matthew Wolfson 

16561 N. 92nd Street,
Suite 101 

Scottsdale, AZ
85260 

Email: ceo@electromedtech.com

 

If to JRD, to:

 

JR-HD Enterprises
III, LLC 

Attn: Jeff Ramson 

150 East 58th Street,
20th Floor 

New York, NY 10155 

Email: Jramson@pcgadvisory.com

 

With a copy, which
shall not constitute notice, to:

 

Gerald A. Adler 

Adler Silverberg
PLLC 

48 Wall Street,
Suite 1100 

New York, NY 10005

 

    Page 7 of 8

     

    

 

Any Party may change
its address for notices hereunder upon notice to each other Party in the manner for giving notices hereunder. Any notice hereunder shall
be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch, if sent by overnight
courier, (iii) upon dispatch, if transmitted by email with return receipt requested and received and (iv) three (3) days
after mailing, if sent by registered or certified mail.

 

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the date first set forth above.

 

	 	EMED:  
	 	 
	 	ELECTROMEDICAL TECHNOLOGIES, INC.  
	 	 
	 	By:	                                 
	 	Name: Matthew Wolfson
	 	Title: Principal Executive Officer, Sole Director    
	 	 
	 	 
	 	JR-HD ENTERPRISES III, LLC:  
	 	 
	 	By:	 
	 	Name: Jeff Ramson
	 	Title: Manager

 

    Page 8 of 8Exhibit 10.23

 

SETTLEMENT AGREEMENT &
RELEASE

 

This Settlement Agreement &
Release ("Agreement"), dated this 1st day of December, 2021, is by and between:

 

		•	Electromedical
                                            Technologies, Inc. a Delaware corporation having a principal place of business at 16561
                                            N. 92nd Street, Ste. 101, Scottsdale, AZ 85260 ("EMED");

 

		•	Blue
                                            Ridge Enterprises, LLC, a California limited liability company (“Blue Ridge”),
                                            having a principal place of business at 5256 South Mission Road, Ste. 104, Bonsall, CA 92003;

 

		•	Donald
                                            Steinberg (“Steinberg”), in his capacities as Blue Ridge’s sole member
                                            and manager and as an individual, having an address of record of 3223 Sumac Road, Fallbrook
                                            CA; and,

 

		•	Dianna
                                            Kaplan (“Kaplan”), an individual and former spouse of Steinberg, with an address
                                            of Le Chateau Village, 1 Rue De Saverdun, St. Martin D’Oydes 09100, France

 

EMED, Blue Ridge, Steinberg and Kaplan may be
collectively referred to as the “Parties.”

 

RECITALS:

 

WHEREAS,
beginning on December 14, 2018, and terminating on July 1, 2020, EMED issued to Steinberg and Blue Ridge a series
of promissory notes, an accounting of which is attached to this Agreement as Exhibit 1, containing all principal and interest owed,
and fully incorporated herein by reference. The Parties confirm that the promissory notes listed on Exhibit 1 fully and completely
list all outstanding promissory notes issued by EMED to Steinberg or Blue Ridge as of the date hereof (the “EMED Notes”).

 

WHEREAS,
Steinberg and Kaplan were formerly husband and wife. On June 15, 2020, Kaplan filed a petition for divorce under case
number 20FL003764N in the Superior Court for the State of California, County of San Diego. On April 16, 2021, the Court entered
judgment of dissolution of their marriage.

 

    1

     

    

 

WHEREAS,
the judgment of dissolution included a global agreement executed between Steinberg and Kaplan (the “Global Agreement”),
which dealt with the resolution of many of the interests between Steinberg and Kaplan, including with respect to Electromedical Technologies, Inc.
By operation of the Global Agreement, among other provisions, Kaplan is entitled to fifty percent (50%) in and to all of Steinberg’s
right, title and interest in and to any Electromedical equity, rights, preferences, future issuances or other assets, whether direct
or indirect, including by way of Steinberg’s direct or indirect ownership of Blue Ridge or any other entity, including by way of
loan, note or agreement to or in favor of EMED or any of EMED’s shareholders, directors, officers, employees or affiliates, including
the EMED Notes.

 

WHEREAS,
EMED owes Blue Ridge and Steinberg a balance due of $231,500 in principal and $18,370.27 in interest on all outstanding EMED
Notes, totaling $249,870.27.

 

WHEREAS,
the Parties entered into good faith discussions to retire the balance of principal and interest owed under the EMED Notes,
and the Parties deem it to be in their shared best interests to avoid the commencement of legal action, including, but not limited to
(i) a civil action for damages filed in any court of competent jurisdiction, (ii) an arbitration in any venue, or (iii) any
other civil action of any kind or sort consistent with any applicable law and the EMED Notes, and to resolve any and all disputes between
them finally and forever regarding the EMED Notes in order to avoid the inconvenience, costs and expenses related to any and all such
legal actions, upon the terms and condition set forth herein, including the application of California law to this Agreement; and,

 

NOW
THEREFORE, in consideration for the mutual promises and covenants contained herein, the sufficiency of which is hereby acknowledged,
the Parties hereto agree as follows:

 

Section 1.     Incorporation
of the RECITALS clauses.

 

1.1. The Parties acknowledge
that all of the representations set forth in the RECITALS clauses of this Agreement are incorporated herein by reference and made a material
part of this Agreement with the same force and effect as if more fully set forth here at. The Parties waive any rule of contract
construction or legal presumption that would prohibit any court of competent jurisdiction from construing or enforcing this Agreement
based upon the contents of the RECITALS above.

 

    2

     

    

 

Section 2.     Settlement
Payment, Document Delivery; Release of All Claims.

 

2.1. Settlement Payment.
Upon the execution of this Agreement, EMED will pay Kaplan in satisfaction of her interest under the Global Agreement in the EMED
Notes as follows:

 

2.2. Upon execution of this
Agreement, EMED will immediately pay Kaplan sixty-two thousand, four hundred and sixty-seven dollars, and fifty-seven cents ($62,467.57).

 

2.3. Within thirty business
days of execution of this Agreement by the Parties, EMED will pay Kaplan sixty-three thousand, one hundred and fifty-two dollars, and
thirty-seven cents ($63,152.37), inclusive of additional interest from the effective date hereof until the date of the second payment
in the amount of $684.80 (the payments described in Section 2.2 and 2.3, together, the “Funds”).

 

2.4. Further, upon the execution
of this Agreement, EMED shall issue to Blue Ridge two million (2,000,000) shares of EMED restricted common stock in complete, full and
final satisfaction of any and all claims Steinberg and Blue Ridge has or may have, know or unknown, against EMED that arise from the
EMED Notes in any manner whatsoever. The two million shares shall be subject to a lock up and leak out agreement restricting aggregate
sales of the shares to five hundred thousand (500,000) shares per month.

 

2.5.            The
Funds shall be distributed to Kaplan electronically transferred as follows: Wise Bank part of the Community Federal Savings Bank (CFSB);
Account Holder: Dianna Kaplan; Wire Routing Number: 026073008; Account Number: 822000088878; Address: 19 W 24th Street, New
York, NY 10010.

 

2.6.            Release
of All Claims. Immediately upon satisfaction of this Agreement by receipt by Kaplan of the Funds in immediately available funds and
the issuance of the restricted common stock to Steinberg, including execution of the lock up leak out agreement by Steinberg, the remainder
of this Agreement shall go into effect. Except as provided for herein, and in further consideration of the mutual covenants hereto, EMED,
Blue Ridge, Steinberg and Kaplan agree on behalf of themselves, and their respective successors, assigns, officers, directors, shareholders,
attorneys, employees, agents, independent contractors, affiliates, control persons, administrators, and any and all persons or business
entities acting by and through each of them as the case may be, to irrevocably and unconditionally remise, release, acquit, satisfy and
forever discharge each other, specifically including their agents, directors, officers, affiliates, employees representatives, insurance
carriers, attorneys, divisions and subsidiaries, (and all agents, directors, officers, employees, representatives, insurance carriers,
and attorneys of such divisions and subsidiaries), and their predecessors, successors, administrators and assigns, and all persons acting
by, through, under, or in concert with any of them (collectively "Releases"), of and from any and all claims, actions, causes
of action, suits, debts, charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, and expenses
(including attorney fees and costs actually incurred), of any nature whatsoever, known or unknown, in law or equity, arising out of the
EMED Notes.

 

    3

     

    

 

2.7. Except as for any specific
rights created by virtue of this Agreement and the Global Agreement, EMED, Blue Ridge, Steinberg and Kaplan promise not to institute
any future suits or proceedings at law or in equity or any arbitration or administrative proceedings against each other for or on account
of any claim or cause of action arising specifically out of the EMED Notes, with the exception of any rights, claims or causes of action
accruing to Kaplan after the effective date hereof, should Steinberg and/or Blue Ridge, or any affiliated person or entity acting on
behalf of Steinberg, enter into any future contracts with EMED that result in Steinberg acquiring, directly or indirectly, any right,
title and interest in and to any EMED equity, rights, preferences, cash, future issuances or other assets.

 

2.8.            This
is intended as a full and complete release and discharge of any or all claims that EMED, Blue Ridge, Steinberg and Kaplan may or might
have or had against each other regarding the EMED Notes, qualified by the terms and conditions of Section 2.8, and EMED, Blue Ridge,
Steinberg and Kaplan do so in full and final settlement, release and discharge of any and all such claims and the Parties intend to and
do forever hereby release and discharge each other of and from any and all liability of any nature related to the EMED Notes.

 

2.10 This Agreement constitutes
a compromise, settlement, and release of claims and is being entered into solely to avoid the burden, inconvenience, and expense of litigating
those claims. No Party to this Agreement admits any liability to the other Party with respect to any such claim or any other matter.
Each Party expressly denies liability as to every claim, which may be asserted by the other Party. Therefore, this Agreement is not to
be and shall never be construed or deemed an admission or concession by any of the Parties hereto of liability or culpability at any
time for any purpose concerning any claim being compromised, settled, and released, or any other matter.

 

    4

     

    

 

Section 3.     Miscellaneous
Provisions.

 

3.1. Notices. All
notices, offers of other communications required or permitted to be given pursuant to this Agreement shall be in writing and shall be
considered as properly given or made (i) if delivered personally; or (ii) upon receipt by facsimile transmission (with written
confirmation of receipt) or confirmed electronic mail; or (iii) after the expiration of the second business day following deposit
with documented overnight delivery service; or (iv) five business days of transmission by regular mail. All notices given or made
pursuant hereto shall be so given or made to the parties at the following addresses:

 

	If to EMED:  	Electromedical
    Technologies, Inc.  
	 	Attention:
    Mr. Matthew Wolfson 
	 	16561 N.
    92nd Street, Ste. 101  
	 

     
	 Scottsdale,
    AZ 8526  
	If to Blue Ridge: 	Blue Ridge
    Enterprises, LLC 
	 	Attention: Mr. Donald
                                 Steinberg

    5256 South Mission Road, Ste. 104

	 

     
	Bonsall,
    CA 92003 
	If to Steinberg: 	Mr. Donald
    Steinberg 
	 	3223 Sumac Road
	 	Fallbrook CA 92003
	 	 
	If to Kaplan:	Ms. Dianna Kaplan
	Le Chateau Village, 1 Rue De Saverdun

                                diannakaplan1@gmail.com
	St. Martin D’Oydes 09100, France

 

The address of any party hereto may be changed
by a notice in writing given in accordance with the provisions hereof.

 

3.2. Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, or unenforceable, such provision
shall be severed and enforced to the extent possible or modified in such a way as to make it enforceable, and the invalidity, illegality
or unenforceability thereof shall not affect the validity, legality, or enforceability of the remaining provisions of this Agreement.

 

    5

     

    

 

3.3. Binding on Affiliated
Third Parties. This Agreement shall inure to the benefit of and shall be binding upon EMED, Blue Ridge, Kaplan and Steinberg and
their respective agents, representatives, executors, administrators, trustees, personal representatives, partners, directors, officers,
shareholders, agents, attorneys, insurers, employees, representatives, predecessors, successors, heirs, and assigns.

 

3.4. Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard to principles
of conflict of laws. Any controversy or claim arising out of or relating to this Agreement or the breach thereof, shall be settled by
civil action in the federal or state courts sitting in San Diego, California. In the event any civil action is commenced, the prevailing
party shall be determined by a court, and the court shall award the prevailing party its attorney fees as an element of costs.

 

3.5. Counterparts.
This Agreement may be executed in multiple counterparts, all of which shall be deemed originals, and with the same effect as if all Parties
had signed the same document. All of such counterparts shall be construed together with and shall constitute one Agreement, but in making
proof, it shall only be necessary to produce one such counterpart. A facsimile or email transmission shall be as valid and enforceable
as an original.

 

3.6. Entire Understanding.
This Agreement is the entire, final, and complete agreement of the Parties relating to the subject of this Agreement and supersedes
and replaces all prior or existing written and oral agreements between the Parties or their representatives relating thereto.

 

3.7. Further Assurances.
The parties agree to execute and deliver to each other such other documents, and to do such other acts and things, all as the other
party may reasonably request for the purpose of carrying out the intent of this Agreement.

 

3.8.  Amendments.
This Agreement shall not be amended or otherwise modified unless in writing signed by all of the parties hereto.

 

    6

     

    

 

3.9. Acknowledgment.
EMED, Blue Ridge, Kaplan and Steinberg acknowledges (i) each has read this Agreement including all exhibits completely, and have
consulted with their respective attorneys concerning its contents and legal consequences, and have requested any change in language necessary
or desirable to effectuate their intent and expectations so that the rule of construction of contracts construing ambiguities against
the drafting party shall be inapplicable; (ii) they have taken all corporate actions and obtained all corporate authorizations,
consents and approvals, if applicable, as are conditions precedent to their authority to execute this Agreement, and thus warrant that
they are fully authorized to bind the Party for which they execute this Agreement; and, (iii) there has been and will be no assignment
or other transfer of any claim released herein, or any part thereof, and each Party agrees to defend, indemnify and hold harmless the
other party from any claims, obligations, or other liabilities, including specifically attorney’s fees and costs incurred, which
result from the assertion by any third party of a right to any claim which is released by this Agreement. The foregoing warranties and
representations shall survive the execution and delivery of this Agreement. Blue Ridge, Steinberg, and Kaplan each acknowledge that except
for the resolution regarding the EMED Notes herein, no part of the Global Agreement between Kaplan and Steinberg is modified in any way,
shape, or form and that the Global Agreement continues in full force and effect and each of Steinberg and Kaplan reaffirm their agreement
with all provisions in the Global Agreement.

 

3.10. Assignment.
This Agreement shall be binding upon and inure to the benefit of each party hereto or to such party's heirs, executors, administrators,
successors and assigns and nothing in this Agreement, express or implied, is intended to confer upon any other person any rights or remedies
of any nature whatsoever under or by reason of this Agreement. No Party to this Agreement may assign or delegate any of its rights under
this Agreement.

 

3.11. Confidentiality.
Each of the parties represents and agrees that it will keep the terms, provisions and amounts in this Agreement confidential and
that it will not, without the consent of the other Party, disclose, divulge or furnish such confidential information to any person other
than their immediate families, their attorney and accountant (all of whom will be informed of and bound by this confidentiality provision)
except as required by law or, if necessary, to any applicable taxing authorities.

 

3.12.  Payments.
All references to dollar amounts in this Agreement shall be to United States dollars.

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have signed this agreement upon the date first written above.

 

	ELECTROMEDICAL TECHNOLOGIES, INC.	 
	 	 	 
	 	 	 
	By:		 
	Name:	MATTHEW WOLFSON	 
	Title:	Principal Executive Officer	 
	 	 	 
	 	 	 
	BLUE RIDGE ENTERPRISES, LLC	 
	 	 	 
	 	 	 
	By:		 
	Name:	DONALD STEINBERG	 
	Title:	Manager	 
	 	 	 
	 	 	 
	DONALD STEINBERG	 
	 	 	 
	 	 	 
	By:		 
	Name:	DONALD STEINBERG	 
	Title:	An Individual	 

 

    8

     

    

 

	DIANNA KAPLAN	 
	 	 	 
	 	 	 
	By:		 
	Name:	DIANNA KAPLAN	 
	Title:	Individually	 

 

    9

     

    

 

	Name	TYPE	Date	Amount	07/30/2020	08/04/2020
	 	 	 	 	Ͳ5,000.00	Ͳ10,000.00
	Donloans	RelatedPartyNotepayable	12/14/2018	$75,000.00	 	 
	Donloans	RelatedPartyNotepayable	12/19/2018	$15,000.00	 	 
	Donloans	RelatedPartyNotepayable	12/28/2018	$15,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/12/2019	$12,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/26/2019	  $20,000.00	$(5,000.00)	$(10,000.00)
	Donloans	RelatedPartyNotepayable	02/28/2019	$15,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/06/2019	$5,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/22/2019	$20,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/29/2019	$20,000.00	 	 
	Donloans	RelatedPartyNotepayable	04/01/2019	$5,000.00	 	 
	Donloans	RelatedPartyNotepayable	04/25/2019	$10,000.00	 	 
	Donloans	RelatedPartyNotepayable	04/26/2019	$10,000.00	 	 
	Donloans	RelatedPartyNotepayable	04/30/2019	$20,000.00	 	 
	Donloans	RelatedPartyNotepayable	05/02/2019	$20,000.00	 	 
	Donloans	RelatedPartyNotepayable	05/07/2019	$5,000.00	 	 
	Donloans	RelatedPartyNotepayable	05/09/2019	$20,000.00	 	 
	Donloans	RelatedPartyNotepayable	05/10/2019	$12,000.00	 	 
	Donloans	RelatedPartyNotepayable	06/07/2019	$9,000.00	 	 

 

     

     

    

 

	Donloans	RelatedPartyNotepayable	11/27/19	$10,000.00	 	 
	Donloans	RelatedPartyNotepayable	01/08/2020	$5,000.00	 	 
	Donloans	RelatedPartyNotepayable	01/15/2020	$4,000.00	 	 
	Donloans	RelatedPartyNotepayable	01/17/2020	$3,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/04/2020	$5,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/18/2020	$11,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/21/2020	$10,000.00	 	 
	Donloans	RelatedPartyNotepayable	02/28/2020	$3,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/02/2020	$4,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/03/2020	$3,000.00	 	 
	Donloans	RelatedPartyNotepayable	03/04/20	$10,000.00	 	 
	Donloans	RelatedPartyNotepayable	05/05/20	$11,500.00	 	 
	Donloans	RelatedPartyNotepayable	07/01/20	$15,000.00	 	 
	Donloans	 	 	$402,500.00	$(5,000.00)	$(10,000.00)

  

     

     

    

 

 

	08/14/2020	08/20/2020	09/24/2020	10/20/2020	12/04/2020	12/16/2020	01/12/2021
	Ͳ5,000.00	Ͳ15,000.00	Ͳ10,000.00	Ͳ10,000.00	T10,000.00	Ͳ5,000.00	Ͳ10,000.00
	 	 	 	 	 	 	 
	 	$(15,000.00)	 	 	 	 	 
	 	 	 	 	$(10,000.00)	$(5,000.00)	 
	 	 	 	 	 	 	 
	$(5,000.00)	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	$(10,000.00)
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	$(10,000.00)	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

     

     

    

 

	 	 	 	 	 	 	 
	 	 	 	$(10,000.00)	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	$(5,000.00)	$(15,000.00)	$(10,000.00)	$(10,000.00)	$(10,000.00)	$(5,000.00)	$(10,000.00)
	 	 	 	 	 	 	$332,500.00

 

     

     

    

 

	01/14/2021	2/16/2021	2/26/2021	3/9/2021	3/16/2021	04/02/2021	04/13/2021
	Ͳ10,000.00	Ͳ10,000.00	Ͳ5,000.00	Ͳ5,000.00	Ͳ10,000.00	-5,000.00	-10,000.00
	 	 	 	 	$(10,000.00)	$(5,000.00)	$(10,000.00)
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	$(5,000.00)	 	 	 	 	 
	$(10,000.00)	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	$(5,000.00)	 	 	 	 	 
	 	 	$(5,000.00)	$(5,000.00)	 	 	 

 

     

     

    

 

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	$(10,000.00)	$(10,000.00)	$(5,000.00)	$(5,000.00)	$(10,000.00)	$(5,000.00)	$(10,000.00)

 

     

     

    

 

	04/28/2021	05/20/2021	05/21/2021	05/27/2021	06/04/2021	06/10/2021	06/14/2021	06/21/2021
	-2,000.00	-2,000.00	-1,000.00	-1,000.00	-2,000.00	-2,000.00	-2,000.00	-2,000.00
	$(2,000.00)	$(2,000.00)	$(1,000.00)	$(1,000.00)	$(2,000.00)	$(2,000.00)	$(2,000.00)	$(2,000.00)
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 

 

     

     

    

 

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	$(2,000.00)	$(2,000.00)	$(1,000.00)	$(1,000.00)	$(2,000.00)	$(2,000.00)	$(2,000.00)	$(2,000.00)

 

     

     

    

 

	06/24/2021	7/9/2021	7/21/2021	7/30/2021	8/9/2021	8/20/2021	9/1/2021	9/9/2021
	-1,000.00	Ͳ3,000.00	Ͳ2,000.00	Ͳ3,000.00	Ͳ1,000.00	Ͳ3,000.00	Ͳ2,000.00	Ͳ3,500.00
	$(1,000.00)	$(3,000.00)	$(2,000.00)	$(3,000.00)	$(1,000.00)	$(3,000.00)	$(2,000.00)	$(3,500.00)
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 

 

     

     

    

 

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	$(1,000.00)	$(3,000.00)	$(2,000.00)	$(3,000.00) 	$(1,000.00) 	$(3,000.00)	$(2,000.00)	$(3,500.00)

 

     

     

    

 

	9/24/2021	10/1/2021	Balance	duedate
	Ͳ1,500.00	Ͳ2,000.00	 	 
	$(1,500.00)	$(2,000.00)	$14,000.00	12/13/2020
	 	 	$Ͳ	12/18/2020
	 	 	$Ͳ	12/27/2020
	 	 	$12,000.00	2/11/2021
	 	 	$Ͳ	 2/25/2021
	 	 	$15,000.00	2/27/2021
	 	 	$Ͳ	3/5/2021
	 	 	$Ͳ	 3/21/2021
	 	 	$20,000.00	3/28/2021
	 	 	$Ͳ	 3/31/2021
	 	 	$Ͳ	 4/24/2021
	 	 	$Ͳ	 4/25/2021
	 	 	$20,000.00	4/29/2021
	 	 	$20,000.00	5/1/2021
	 	 	$5,000.00	5/6/2021
	 	 	$20,000.00	5/8/2021

 

     

     

    

 

 

	 	 	$12,000.00	5/9/2021
	 	 	$9,000.00	6/6/2021
	 	 	$Ͳ	11/26/2020
	 	 	$5,000.00	1/7/2021
	 	 	$4,000.00	1/14/2021
	 	 	$3,000.00	1/16/2021
	 	 	$5,000.00	2/3/2021
	 	 	$11,000.00	2/17/2021
	 	 	$10,000.00	2/20/2021
	 	 	$3,000.00	2/27/2021
	 	 	$4,000.00	3/2/2021
	 	 	$3,000.00	3/3/2021
	 	 	$10,000.00	3/4/2021
	 	 	$11,500.00	5/5/2021
	 	 	$15,000.00	7/1/2021
	 	$(1,500.00) 	$(2,000.00)	$231,500.00

 

     

     

    

 

	Name	TYPE	Date	 Amount	07/30/2020	08/04/2020
	 	 	 	 	-5,000.00  	-10,000.00
	Don loans	Related Party	12/14/2018	 $	75,000.00	 	 
	Don loans	Related Party 	12/19/2018	 $	15,000.00	 	 
	Don loans	Related Party 	12/28/2018	 $	15,000.00	 	 
	Don loans	Related Party 	02/12/2019	 $	12,000.00	 	
	Don loans	Related Party 	02/26/2019	 $	20,000.00	$	(5,000.00) 	$	(10,000.00)
	Don loans	Related Party 	02/28/2019	 $	15,000.00	 	 
	Don loans	Related Party 	03/06/2019	 $	5,000.00	 	 
	Don loans	Related Party 	03/22/2019	 $	20,000.00	 	 
	Don loans	Related Party 	03/29/2019	 $	20,000.00	 	 
	Don loans	Related Party 	04/01/2019	 $	5,000.00	 	 
	Don loans	Related Party 	04/25/2019	 $	10,000.00	 	 
	Don loans	Related Party 	04/26/2019	 $	10,000.00	 	 
	Don loans	Related Party 	04/30/2019	 $	20,000.00	 	 
	Don loans	Related Party 	05/02/2019	 $	20,000.00	 	 
	Don loans	Related Party 	05/07/2019	 $	5,000.00	 	 
	Don loans	Related Party 	05/09/2019	 $	20,000.00	 	 
	Don loans	Related Party 	05/10/2019	 $	12,000.00	 	 
	Don loans	Related Party 	06/07/2019	 $	9,000.00	 	 
	Don loans	Related Party 	11/27/19	 $	10,000.00	 	 
	Don loans	Related Party 	01/08/2020	 $	5,000.00	 	 
	Don loans	Related Party 	01/15/2020	 $	4,000.00	 	 
	Don loans	Related Party 	01/17/2020	 $	3,000.00	 	 
	Don loans	Related Party 	02/04/2020	 $	5,000.00	 	 
	Don loans	Related Party 	02/18/2020	 $	11,000.00	 	 
	Don loans	Related Party 	02/21/2020	 $	10,000.00	 	 
	Don loans	Related Party 	02/28/2020	 $	3,000.00	 	 
	Don loans	Related Party 	03/02/2020	 $	4,000.00	 	 
	Don loans	Related Party 	03/03/2020	 $	3,000.00	 	 
	Don loans	Related Party 	03/04/20	 $	10,000.00	 	 
	Don loans	Related Party 	05/05/20	 $	11,500.00	 	 
	Don loans	Related Party 	07/01/20	$ 	15,000.00	 	 
	 	 	 	$ 	402,500.00	 $ 	(5,000.00)	$ 	(10,000.00)

 

    

     

    

 

Don loans

 

	08/14/2020	08/20/2020	09/24/2020	10/20/2020	12/04/2020	12/16/2020
	-5,000.00  	-15,000.00  	-10,000.00  	-10,000.00  	-10,000.00  	-5,000.00  
	 	$ (15,000.00)	 	 	 	 
	 	 	 	 	$ (10,000.00)	$ (5,000.00)
	$ (5,000.00)	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	$ (10,000.00)	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	$ (10,000.00)	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	$ (5,000.00)	 $ (15,000.00)	 $ (10,000.00) $ 	(10,000.00) 	$ (10,000.00)	 $ (5,000.00)
	 	 	 	 	 	$ 332,500.00

 

    

     

    

 

	01/12/2021	01/14/2021	2/16/21	2/26/21	3/9/21	3/16/21
	-10,000.00  	-10,000.00  	-10,000.00  	-5,000.00  	-5,000.00  	-10,000.00
	 	 	 	 	 	$ (10,000.00)
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	$ (5,000.00)	 	 	 
	$ (10,000.00)	$ (10,000.00)	 	 	 	 
	 	 	$ (5,000.00)	 	 	 
	 	 	 	$ (5,000.00)	$ (5,000.00)	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	$ (10,000.00)	$ (10,000.00)	$ (10,000.00)	$ (5,000.00)	$ (5,000.00)	$ (10,000.00)
	 	 	 	 	 	 
	 	 	 	 75,000.00	$ 75,000.00	$ 65,000.00
	 	 	 	 	$ 18.00	 
	 	 	 	 	75	 
	 	 	 	 	$ 369.86	$ 1,541.10

 

	3/31/21	04/02/2021	04/13/2021	04/28/2021	05/20/2021	05/21/2021
	 	-5,000.00	  -10,000.00	  -2,000.00	  -2,000.00	  -1,000.00  
	 	 $       (5,000.00)	 $    (10,000.00)	$          (2,000.00)	$          (2,000.00)	$          (1,000.00)
	 	 $       (5,000.00)	 $    (10,000.00)	$          (2,000.00)	$          (2,000.00)	$          (1,000.00)
	 	$      60,000.00	$      50,000.00	$          48,000.00	$          46,000.00	$          45,000.00
	15	2	11	15	22	1

 

    

     

    

 

	$	267.12	$	35.62	$	180.82	$	205.48	$	289.32	$	12.60
	05/27/2021	 	06/04/2021	 	06/10/2021	 	06/14/2021	 	06/21/2021	 	06/24/2021	 
	 	-1,000.00	 	-2,000.00	 	-2,000.00	 	-2,000.00	 	-2,000.00	 	-1,000.00  
	$	(1,000.00)	$	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(1,000.00)

 

	 	 	$	 	$	 	 	 	 		 	 
	$	 	$	 	$	 	 	 	 	 	 	 

 

    

     

    

 

	 	$ (5,000.00)	$ (10,000.00)	$ (2,000.00)	$ (2,000.00)	$ (1,000.00)
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 $       (5,000.00)	 $    (10,000.00)	$          (2,000.00)	$          (2,000.00)	$          (1,000.00)
	 	$      60,000.00	$      50,000.00	$         48,000.00	$         46,000.00	$         45,000.00
	 	 	 	 	 	 
	15	2	11	15	22	1

 

    

     

    

 

	$	267.12	$	35.62	$	180.82	$	205.48	$	289.32	$	12.60
	05/27/2021	 	06/04/2021	 	06/10/2021	 	06/14/2021	 	06/21/2021	 	06/24/2021	 
	 	-1,000.00	 	-2,000.00	 	-2,000.00	 	-2,000.00	 	-2,000.00	 	-1,000.00  
	$	(1,000.00)	$	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(1,000.00)

 

	 	 	$	 	$	 	 	 	 		 	 
	$	 	$	 	$	 	 	 	 	 	 	 

 

    

     

    

 

	$	(1,000.00)	$ 	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(2,000.00)	$	(1,000.00)
	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 
	$	44,000.00	 	42,000.00	$	40,000.00	 	38,000.00	$	36,000.00	$	35,000.00
	3	 	6	 	8	 	6	 	4	 	7	 
	 	73.97	 	96.44	$	69.04	 	43.84	$	72.88	$	29.59

 

    

     

    

 

	6/30/21	7/9/21	7/21/21	7/30/21	8/9/21	8/20/21
	 	-3,000.00  	-2,000.00  	-3,000.00  	-1,000.00  	-3,000.00  
	 	 $          (3,000.00)	$          (2,000.00)	$          (3,000.00)	$          (1,000.00)	$          (3,000.00)
	 	 	 	 	 	 
	 	 $          (3,000.00)	$          (2,000.00)	$          (3,000.00)	$          (1,000.00)	$          (3,000.00)
	$ 35,000.00	32,000.00	$ 30,000.00	27,000.00	$26,000.00	$23,000.00
	6	9	12	9	10	11

 

	 	 	$	 	$	 	 	 	 		 	 
	$	 	$	 	$	 	 	 	 	 	 	 

 

    

     

    

 

	57.53	86.30	$ 105.21	73.97	$ 73.97	$ 78.36
	9/1/21	9/9/21	9/24/21	9/30/21	10/1/21	 Balance 
	-2,000.00  	-3,500.00  	-1,500.00  	 	-2,000.00  	 
	 $          (2,000.00)
	$          (3,500.00)	 $          (1,500.00)	 	 $          (2,000.00)	
    $ 14,000.00

    $ -

    $ -

    $ 12,000.00

    $ -

    $ 15,000.00

    $ -

    $ -

    $ 20,000.00

    $ -

    $ -

    $ -

    $ 20,000.00

    $ 20,000.00 $
    5,000.00 $ 20,000.00

    $ 12,000.00

    $ 9,000.00

    $ -

    $ 5,000.00

    $ 4,000.00

    $ 3,000.00

    $ 5,000.00 $ 11,000.00

    $ 10,000.00 $
    3,000.00

    $ 4,000.00

    $ 3,000.00 $ 10,000.00

    $ 11,500.00

    $ 15,000.00

	 $          (2,000.00)
    	$          (3,500.00)
    	$          (1,500.00)	 $                             -	$          (2,000.00)	 $      231,500.00
    
	$ 21,000.00	17,500.00	     $ 16,000.00	16,000.00	$14,000.00	 
	12	8	     15	6	60	 
	75.62	46.03	     $ 71.92	26.30	$230.14	 

 

	 	 	$	 	 	 	$	 	 		 	 
	$	 	$	 	 	 	$	 	 	 	 	 

 

    

     

    

 

 

	 	 	 	 	 	 	                        3/31/21	 	 	 12/31/20	 	 	6/30/21	 
	due date	 	 	2020 interest	 	 	Days interest	 	 	Q1 - 2021	 	 	Days interest	 	 	Q2 -2021	 	 	Days interest	 
	12/13/20	 	 	$	369.86	 	 	n/a	 	 	$	1,808.22	 	 	n/a	 	 	$	1,167.12	 	 	 	n/a	 
	12/18/20    	 	 	$	16.44	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	12/27/20	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2/11/21    	 	 	 	 	 	 	48	 	 	$	157.81	 	 	91	 	 	$	299.18	 	 	$	92.00	 
	2/25/21	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2/27/21    	 	 	 	 	 	 	32	 	 	$	131.51	 	 	91	 	 	$	373.97	 	 	$	92.00	 
	3/5/21	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3/21/21	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	3/28/21    	 	 	 	 	 	 	3	 	 	$	16.44	 	 	91	 	 	$	498.63	 	 	$	92.00	 
	3/31/21    	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4/24/21    	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4/25/21	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	11/26/20	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	1/7/21	 	 	 	 	 	 	83	 	 	$	113.70	 	 	91	 	 	$	124.66	 	 	$	92.00	 
	1/14/21	 	 	 	 	 	 	76	 	 	$	83.29	 	 	91	 	 	$	99.73	 	 	$	92.00	 
	1/16/21	 	 	 	 	 	 	74	 	 	$	60.82	 	 	91	 	 	$	74.79	 	 	$	92.00	 
	2/3/21	 	 	 	 	 	 	56	 	 	$	76.71	 	 	91	 	 	$	124.66	 	 	$	92.00	 
	2/17/21	 	 	 	 	 	 	42	 	 	$	126.58	 	 	91	 	 	$	274.25	 	 	$	92.00	 
	2/20/21	 	 	 	 	 	 	39	 	 	$	106.85	 	 	91	 	 	$	249.32	 	 	$	92.00	 
	2/27/21	 	 	 	 	 	 	32	 	 	$	26.30	 	 	91	 	 	$	74.79	 	 	$	92.00	 
	3/2/21	 	 	 	 	 	 	29	 	 	$	31.78	 	 	91	 	 	$	99.73	 	 	$	92.00	 
	3/3/21	 	 	 	 	 	 	28	 	 	$	23.01	 	 	91	 	 	$	74.79	 	 	$	92.00	 
	3/4/21	 	 	 	 	 	 	27	 	 	$	73.97	 	 	91	 	 	$	249.32	 	 	$	92.00	 
	4/29/21	 	 	$	154.00	 	 	 	 	 	 	 	 	 	62	 	 	 	 	 	 	 	 	 
	5/1/21	 	 	$	152.00	 	 	 	 	 	 	 	 	 	60	 	 	 	 	 	 	 	 	 
	5/6/21	 	 	$	147.00	 	 	 	 	 	 	 	 	 	55	 	 	 	 	 	 	 	 	 
	5/8/21	 	 	$	145.00	 	 	 	 	 	 	 	 	 	53	 	 	 	 	 	 	 	 	 
	5/9/21	 	 	$	144.00	 	 	 	 	 	 	 	 	 	52	 	 	 	 	 	 	 	 	 
	6/6/21	 	 	$	116.00	 	 	 	 	 	 	 	 	 	24	 	 	 	 	 	 	 	 	 
	5/5/21	 	 	 	 	 	 	 	 	 	 	56	 	$	148.00              	 	 	 	 	 	 
	 7/1/21	 	 	 	 	 	 	91	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	$	386.30	 	 	 	 	 	$	2,836.99	 	 	 	 	 	$	3,784.93	 	 	 	 	 

 

     

     

    

 

	9/30/21	 	 	 	 	 	11/29/21	 	 	 	 	 	 	 	 	 	 
	Q2 -2021	 	 	Days interest	 	 	Q2 -2021	 	 	TOTAL	 	 	Review	 	 	Days	 
	$	637.67	 	 	$	60.00	 	 	$	230.14	 	 	$	4,213.01	 	 	$	4,213.01	 	 	 	351	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	16.44	 	 	$	16.44	 	 	 	346	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	337	 
	$	302.47	 	 	$	60.00	 	 	$	197.26	 	 	$	956.71	 	 	$	956.71	 	 	 	291	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	277	 
	$	378.08	 	 	$	60.00	 	 	$	246.58	 	 	$	1,130.14	 	 	$	1,130.14	 	 	 	275	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	269	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	253	 
	$	504.11	 	 	$	60.00	 	 	$	328.77	 	 	$	1,347.95	 	 	$	1,347.95	 	 	 	246	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	243	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	219	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	218	 
	$	843.84	 	 	$	60.00	 	 	$	328.77	 	 	$	1,172.60	 	 	$	1,172.60	 	 	 	214	 
	$	832.88	 	 	$	60.00	 	 	$	328.77	 	 	$	1,161.64	 	 	$	1,161.64	 	 	 	212	 
	$	201.37	 	 	$	60.00	 	 	$	82.19	 	 	$	283.56	 	 	$	283.56	 	 	 	207	 
	$	794.52	 	 	$	60.00	 	 	$	328.77	 	 	$	1,123.29	 	 	$	1,123.29	 	 	 	205	 
	$	473.42	 	 	$	60.00	 	 	$	197.26	 	 	$	670.68	 	 	$	670.68	 	 	 	204	 
	$	286.03	 	 	$	60.00	 	 	$	147.95	 	 	$	433.97	 	 	$	433.97	 	 	 	176	 
	 	 	 	 	 	 	 	 	 	 	 	 	$	-	 	 	$	-	 	 	 	368	 
	$	126.03	 	 	$	60.00	 	 	$	82.19	 	 	$	446.58	 	 	$	446.58	 	 	 	326	 
	$	100.82	 	 	$	60.00	 	 	$	65.75	 	 	$	349.59	 	 	$	349.59	 	 	 	319	 
	$	75.62	 	 	$	60.00	 	 	$	49.32	 	 	$	260.55	 	 	$	260.55	 	 	 	317	 
	$	126.03	 	 	$	60.00	 	 	$	82.19	 	 	$	409.59	 	 	$	409.59	 	 	 	299	 
	$	277.26	 	 	$	60.00	 	 	$	180.82	 	 	$	858.90	 	 	$	858.90	 	 	 	285	 
	$	252.05	 	 	$	60.00	 	 	$	164.38	 	 	$	772.60	 	 	$	772.60	 	 	 	282	 
	$	75.62	 	 	$	60.00	 	 	$	49.32	 	 	$	226.03	 	 	$	226.03	 	 	 	275	 
	$	100.82	 	 	$	60.00	 	 	$	65.75	 	 	$	298.08	 	 	$	298.08	 	 	 	272	 
	$	75.62	 	 	$	60.00	 	 	$	49.32	 	 	$	222.74	 	 	$	222.74	 	 	 	271	 
	$	252.05	 	 	$	60.00	 	 	$	164.38	 	 	$	739.73	 	 	$	739.73	 	 	 	270	 
	$	466.30	 	 	$	60.00	 	 	$	189.04	 	 	$	655.34	 	 	$	655.34	 	 	 	208	 
	$	373.97	 	 	$	60.00	 	 	$	246.58	 	 	$	620.55	 	 	$	620.55	 	 	 	151	 
	$	7,556.58	 	 	 	 	 	 	$	3,805.48	 	 	$	18,370.27	 	 	$	18,370.27	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	$	-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

     

     

    

 

LOCK-UP AND LEAK OUT AGREEMENT

 

This LOCK-UP AND LEAK-OUT AGREEMENT
(the “Agreement”) is made as of December 1, 2021 (the “Effective Date”) by and between Electromedical
Technologies, Inc., a Delaware corporation, (the “Company”), and Donald Steinberg and Blue Ridge Enterprises, LLC
(collectively, “Steinberg”). Steinberg is beneficial owners of two million (2,000,000) restricted common shares
(“Shares”) of the Company.

 

WHEREAS,
reference is made to that particular Settlement Agreement and Release dated December 1, 2021 between the Company, Kaplan and Steinberg,
attached hereto and incorporated herein by reference as a material part hereof.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the undersigned Stockholder agree as follows:

 

1. Prohibition
on Sales or Transfers. Except as otherwise provided herein, Steinberg will not offer, sell, contract to sell, pledge, give, donate,
transfer or otherwise dispose of, directly or indirectly, the two million Shares of common stock of the Company (the “Common Stock
 ”) (the “Lock-Up Shares”) or securities or rights convertible into or exchangeable or exercisable for any Lock-Up Shares,
enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole
or in part, any of the economic or voting consequences of ownership of such securities, whether any such aforementioned transaction is
to be settled by delivery of the Lock-Up Shares or such other securities, in cash or otherwise, or publicly disclose the intention to
make any such offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement (the “Lock-Up
Agreement”). As used in this Agreement “Affiliated Entities” shall mean any legal entity, including any corporation,
limited liability company, partnership, not-for-profit corporation, estate planning vehicle or trust, which is directly or indirectly
owned or controlled by the Stockholder or his descendants or spouse, of which such Stockholder or his descendants or spouse are beneficial
owners, or which is under joint control or ownership with any other person or entity subject to a lock-up agreement regarding the Common
Stock with terms substantially identical to this Agreement.

 

3.            Restrictions
on Sales; Volume Limitations. Beginning November 8, 2021 and ending upon the final sale of the two million shares, Steinberg
shall have the right to effect open market sales of his Common Stock producing proceeds, after payment of brokerage fees, in the amount
of 500,000 shares monthly, (“Sellable Shares”). Sellable Share amounts are not cumulative. If Steinberg
waives his right at any time during any applicable month, pursuant to this Section 2 (“Waivable Period”), the calculated
Sellable Share amounts for those Waivable Periods, shall not be accrued and added to Sellable Shares amounts, in a future quarterly
period.

 

    Page 1 of 4

     

    

 

4.            Attempted
Transfers. Any attempted or purported sale or other Transfer of any Lock Up Shares by the Stockholder in violation or contravention
of the terms of this Agreement shall be null and void ab initio, unless under court order or final divorce judgment. The Company
shall instruct its transfer agent, Pacific Stock Transfer Company, to reject and refuse to transfer on its books any Lock-Up Shares that
may have been attempted to be sold or otherwise Transferred in violation or contravention of any of the provisions of this Agreement and
shall not recognize any person or entity, unless under court order or final divorce judgment.

 

5.            Broker
and Account Verification. The Stockholder agrees and consents to (i) effect sales of the Lock-Up Shares only through Scottsdale
Capital Advisors and/or Wilson Davis; (ii) Provide Mailander Law Office, Inc. with quarterly sales statements regarding Stockholder’s
compliance with the sales limitations in this Agreement; (iii) Authorize Mailander Law Office, Inc. with access to Stockholder’s
account records Scottsdale Capital Advisors and/or Wilson Davis and to any records concerning Stockholder at Pacific Stock Transfer Company;
(iv) the Company’s imposition of the entry of stop transfer instructions with the Company's transfer agent against the transfer
of the Securities held by the undersigned except in compliance with this Lock and LeakOut Agreement.

 

6.            Broker
Authorization. The Stockholder hereby authorizes Scottsdale Capital Advisors and/or Wilson Davis, regarding the Stockholder’s
Lock-Up Shares, to provide directly to the Company and Mailander Law Office, Inc., immediately upon the Company’s request,
a copy of all account statements showing the Lock-Up Shares and all trading activity in the Lock-Up Shares during any quarterly Lock-Up
Period.

 

7.            Waiver
of Claims. The Stockholder hereby irrevocably waives any and all known or unknown claims and rights, whether direct or indirect, fixed
or contingent, that the Stockholder may now have or that may hereafter arise against the Company or any of its affiliates, or any of its
respective officers, directors, stockholders, employees, agents, attorneys or advisors arising out of the negotiation, documentation of
this Agreement.

 

8.            Acknowledgement
of Representation. The Stockholder represents and warrants to the Company that the Stockholder was or had the opportunity to be represented
by legal counsel and other advisors selected by Stockholder in connection with this Agreement. The Stockholder has reviewed this Agreement
with his, her or its legal counsel and other advisors and understands the terms and conditions hereof.

 

9.            Legends
on Certificates. All Lock-Up Shares now or hereafter owned by the Stockholder, except any shares purchased in open market
transactions by the Stockholder, shall be subject to the provisions of this Agreement and the certificates representing such
Lock-Up Shares shall bear the following legends:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
 “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED FOR VALUE
UNLESS THEY ARE REGISTERED UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR UNLESS THE CORPORATION RECEIVES AN OPINION OF
COUNSEL SATISFACTORY TO IT, OR OTHERWISE SATISFIES ITSELF, THAT AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

 

THE SALE,
ASSIGNMENT, GIFT, BEQUEST, TRANSFER, DISTRIBUTION,
PLEDGE, HYPOTHECATION OR OTHER ENCUMBRANCE OR DISPOSITION OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS RESTRICTED
BY AND MAY BE MADE ONLY IN ACCORDANCE WITH THE TERMS OF A LOCK-UP AGREEMENT, A COPY OF WHICH MAY BE EXAMINED AT THE OFFICE
OF THE CORPORATION.

 

    Page 2 of 4

     

    

 

10.            Governing
Law; Venue. This Agreement will be governed as to validity, interpretation, construction, effect and in all other respects by the
internal laws of the State of California, without regard to the conflict of laws principles thereof. Each of the Parties: (i) agrees
that any legal suit, action or proceeding arising out of or relating to this Agreement will be instituted exclusively in the Courts located
in the County of San Diego, in the State of California, or in the United States District Court located in San Diego, California, (ii) waives
any objection that if may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to
the jurisdiction of the Courts located in the County of San Diego, in the State of California, or in the United States District Court
located in San Diego, California in any such suit, action or proceeding. Each the parties further to accept and acknowledge service of
any and all process that may be served in any suit, action or proceeding in the Courts located in County of San Diego, in the State of
California, or in the United States District Court located in San Diego, California. In the event of any legal action, the prevailing
party shall recover, as part of its costs, reasonable attorney fees.

 

11.            Binding
Effect. This Agreement will be binding upon and inure to the benefit of the Company, its successors and assigns and to the Stockholder
and their respective permitted heirs, personal representatives, successors and assigns.

 

12.            Entire
Understanding. This Agreement sets forth the entire agreement and understanding of the parties hereto in respect of the subject matter
hereof and the transactions contemplated hereby and supersedes all prior written and oral agreements, arrangements and understandings
relating to the subject matter hereof. This Agreement may not be changed orally, but may only be changed by an agreement in writing signed
by the party against whom enforcement of any waiver, change, modification or discharge is sought.

 

    Page 3 of 4

     

    

 

13.            Remedies.
The parties hereto acknowledge that money damages are not an adequate remedy for violations of this Agreement and that any party may,
in such party’s sole discretion, apply to any court of competent jurisdiction for specific performance or injunctive relief or such
other relief as such court may deem just and proper in order to enforce this Agreement or prevent any violation hereof and, to the extent
permitted by applicable law, each party hereto waives any objection to the imposition of such relief. All rights, powers and remedies
provided under this Agreement or otherwise available in respect hereof, whether at law or in equity, shall be cumulative and not alternative,
and the exercise or beginning of the exercise of any thereof by any party hereto shall not preclude the simultaneous or later exercise
of any other such right, power or remedy by such party.

 

14.            Counterparts.
This Agreement may be executed by facsimile and in any number of counterparts, each of which shall be deemed to be an original, but all
of which together shall constitute one and the same instrument. Each counterpart may consist of a number of copies each signed by less
than all, but together signed by all, of the parties hereto.

 

IN
WITNESS WHEREOF, the undersigned have caused this Lock-Up Leak-Out Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	 	ELECTROMEDICAL TECHNOLOGIES, INC.
	 	 	 
	 	By:	 
	 	Name: 	MATTHEW WOLFSON
	 	Title:	 Principal Executive Officer

 

Name of Stockholder:
Donald Steinberg and Blue Ridge Enterprises, LLC

 

	Signature of Authorized Signatory of Stockholder 	 	 

 

Telephone Number
of Stockholder: (949) 874-5016

 

Email Address
of Stockholder: don@donaldsteinberg.com

 

Address for Notice
of Stockholder: 3223 Sumac Road Fallbrook CA

 

    Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]